Fixed dose of long‐acting erythropoietic stimulating agents at higher frequency improves appetite, reduces inflammation and corrects anaemia in patients on haemodialysis. (October 2016)

• Record Type: Journal Article
• Authors: Liu, Wen‐Sheng; Chu, Da‐Chen; Chan, Hsiang‐Lin; Li, Szu‐Yuan; Liu, Chih‐Kuang; Yang, Chih‐Yu; Chen, Yu‐Wei; Lee, Pui‐Ching; Lai, Yen‐Ting; Lin, Chih‐Ching
• Is Part Of: Clinical and experimental pharmacology and physiology. Volume 43:Number 10(2016:Oct.)
• Page Start: 875
• Page End: 882
• Publication Date: 2016-10
• Subjects: anaemia -- dosing strategy -- erythropoietin stimulating agent -- haemodialysis -- inflammation -- malnutrition; Clinical pharmacology -- Periodicals; Pharmacology, Experimental -- Periodicals; Physiology, Experimental -- Periodicals; Physiology, Pathological -- Periodicals; 615.1
• DOI: 10.1111/1440-1681.12618
• Languages: English
• ISSNs: 0305-1870

Abstract

Summary: Anaemia is an important issue in patients undergoing haemodialysis. We aimed to identify a better dosing schedule of a fixed monthly dose of continuous erythropoietin receptor activator (CERA) in patients with chronic kidney disease (CKD) on haemodialysis. The CERA dosing schedule included 100 μg once monthly for 2 months, 50 μg twice monthly for 2 months and then 100 μg once monthly for two months. The effectiveness was determined by comparing haematocrit, nutritional status (serum protein and albumin) and inflammatory markers (tumour necrosis factor (TNF)‐α, interleukin (IL)‐1, IL‐6 and Hepcidin) at the beginning of the study with those at the end of the study. Forty‐seven out of 67 patients completed the trial. At the end, haematocrit was significantly higher (34.51 vs 33.22%, P= .004), levels of inflammatory markers were significantly lower (TNF‐α (30.71 vs 35.67 ng/mL, P =.007), IL‐6 (5.12 vs 7.95 ng/mL, P =.033), hepcidin (60.39 vs 74.39 ng/mL, P =.002)), blood glucose levels were significantly lower (112.40 vs 139.02 mg/dL, P =.003) and albumin was significantly higher (4.11 vs 3.98, P =.001). Patients with a better than average response had a lower initial number of red blood cells (3.3 vs 3.6 × 10 6 /mm 3, P =.025) and a lower IL‐1 (3.8 vs 12.9 ng/mL, P =.01). They also had significantly lower blood glucose levels at the end. (91.3 vs 124.0 mg/dL, P =.03). We demonstrate that a fixed monthly dose of CERA at a twice monthly dosing schedule improves nutrition, reduces the inflammation and corrects anaemia in patients on haemodialysis. This finding may provide a new strategy for treating CKD‐related anaemia.